• Home
  • BRACAnalysis CDx®

BRACAnalysis CDx®

png

BRACAnalysis CDx® – Confidently Recommend an Appropriate PARP Inhibitor with Fast and Accurate BRCA1/2 Results

 

Germline BRCA1 and BRCA2 status is a critical biomarker to help you determine the appropriate therapy for your patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer. BRACAnalysis CDx® was designed to quickly provide accurate results so you can confidently recommend the next treatment for your patient without delay.

 

 

 

Companion diagnostic indications

Tumor Type

Biomarker

Therapy

Breast Cancer

Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes

Lynparza® (olaparib)

Talzenna® (talazoparib)

Ovarian Cancer

Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes

Lynparza® (olaparib)-
treatment/maintenance

Rubraca® (rucaparib)

Pancreatic Cancer

Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes

Lynparza® (olaparib)

Prostate Cancer

Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes

Lynparza® (olaparib)

 

For more information please call us or visit www.myriad-oncology.com

 

 

 

 

 

 

No products in the cart.